Comparative Pharmacology
Head-to-head clinical analysis: PHENETRON versus SEMPREX D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENETRON versus SEMPREX D.
PHENETRON vs SEMPREX-D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenetron is an antihistamine that competes with histamine for H1-receptor sites, blocking histamine-mediated effects in the respiratory tract, vascular system, and gastrointestinal tract. It also exhibits anticholinergic and sedative properties.
SEMPREX-D combines acrivastine, a histamine H1 receptor antagonist, and pseudoephedrine, a sympathomimetic amine vasoconstrictor. Acrivastine blocks peripheral histamine-mediated effects, while pseudoephedrine constricts nasal blood vessels to reduce congestion.
Adults: 50 mg intramuscularly every 6 hours as needed.
1 capsule orally every 12 hours; each capsule contains acrivastine 8 mg and pseudoephedrine 60 mg.
None Documented
None Documented
Terminal half-life 12–15 hours; clinically, steady-state achieved in ~3 days
Terminal elimination half-life is approximately 8-12 hours, allowing twice-daily dosing.
Renal: ~70% unchanged; Biliary/Fecal: ~15% as metabolites; 15% unidentified
Renal (approx. 60% as unchanged drug and metabolites), biliary/fecal (approx. 40%).
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination